1
|
Croft MA, Mcdonald JP, Kiland J, Mattison JA, Roth GS, Ingram D, Kaufman PL. Sex as a risk factor regarding presbyopia in the rhesus monkey. PLoS One 2024; 19:e0300476. [PMID: 38635668 PMCID: PMC11025728 DOI: 10.1371/journal.pone.0300476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Accepted: 02/11/2024] [Indexed: 04/20/2024] Open
Abstract
PURPOSE To determine the effect of sex as a risk factor regarding presbyopia. METHODS Maximum accommodation was pharmacologically induced (40% cabachol corneal iontophoresis) in 97 rhesus monkeys (49 males and 48 females) ranging in age from 8 to 36 years old. Accommodation was measured by Hartinger coincidence refractometry. RESULTS Accommodative amplitude measured refractometrically decreased with age, and the rate of change was not different between males and females (p = 0.827). CONCLUSIONS Presbyopia is essentially sex neutral, and no one is spared. There may be modest variations between different populations for various reasons, but essentially it is monotonously predictable. At present there is no biological therapeutic.
Collapse
Affiliation(s)
- Mary Ann Croft
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, United States of America
| | - Jared P. Mcdonald
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, United States of America
| | - Julie Kiland
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, United States of America
| | - Julie A. Mattison
- Translational Gerontology Branch, National Institute on Aging, NIH, Dickerson, MD, United States of America
| | - George S. Roth
- GeroScience Inc. and Prolongevity Technologies LLC, Pylesville, MD, United States of America
| | - Don Ingram
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, United States of America
| | - Paul L. Kaufman
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, United States of America
- Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, United States of America
- McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI, United States of America
| |
Collapse
|
2
|
McGarry A, Hunter K, Gaughan J, Auinger P, Ferraro TN, Pradhan B, Ferrucci L, Egan JM, Moaddel R. An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington's disease. Sci Rep 2024; 14:1101. [PMID: 38212353 PMCID: PMC10784537 DOI: 10.1038/s41598-023-50553-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 12/21/2023] [Indexed: 01/13/2024] Open
Abstract
Huntington's disease (HD) is increasingly recognized for diverse pathology outside of the nervous system. To describe the biology of HD in relation to functional progression, we previously analyzed the plasma and CSF metabolome in a cross-sectional study of participants who had various degrees of functional impairment. Here, we carried out an exploratory study in plasma from HD individuals over a 3-year time frame to assess whether differences exist between those with fast or absent clinical progression. There were more differences in circulating metabolite levels for fast progressors compared to absent progressors (111 vs 20, nominal p < 0.05). All metabolite changes in faster progressors were decreases, whereas some metabolite concentrations increased in absent progressors. Many of the metabolite levels that decreased in the fast progressors were higher at Screening compared to absent progressors but ended up lower by Year 3. Changes in faster progression suggest greater oxidative stress and inflammation (kynurenine, diacylglycerides, cysteine), disturbances in nitric oxide and urea metabolism (arginine, citrulline, ornithine, GABR), lower polyamines (putrescine and spermine), elevated glucose, and deficient AMPK signaling. Metabolomic differences between fast and absent progressors suggest the possibility of predicting functional decline in HD, and possibly delaying it with interventions to augment arginine, polyamines, and glucose regulation.
Collapse
Affiliation(s)
- Andrew McGarry
- Department of Neurology, Cooper University Hospital and Cooper Medical School at Rowan University, Camden, NJ, USA.
| | - Krystal Hunter
- Department of Medicine, Cooper Medical School at Rowan University, Camden, NJ, USA
| | - John Gaughan
- Department of Neurology, Cooper University Hospital and Cooper Medical School at Rowan University, Camden, NJ, USA
| | - Peggy Auinger
- Department of Neurology, Center for Health and Technology, University of Rochester, Rochester, NY, USA
| | - Thomas N Ferraro
- Department of Biomedical Sciences, Cooper Medical School at Rowan University, Camden, NJ, USA
| | - Basant Pradhan
- Department of Psychiatry, Cooper Medical School at Rowan University, Camden, NJ, USA
| | - Luigi Ferrucci
- Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Josephine M Egan
- Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Ruin Moaddel
- Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.
| |
Collapse
|